Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949949 · ClinicalTrials.gov registry record · Phase 1
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 3
- Study locations
NCT00949949: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer, sponsored by Mayo Clinic.
NCT00949949 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 38 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00949949, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy. Drugs used in chemotherapy, such as everolimus, gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Primary Outcome
Tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG everolimus
- DRUG gemcitabine hydrochloride
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT00949949 record still lists
NCT00949949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00949949 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00949949 about?
NCT00949949 is a clinical study titled "Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy". This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy. Drugs used in chemotherapy, such as everolimus, gemcitabine hydrochloride, and cisplati...
What is the current status of trial NCT00949949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2009-09. Estimated completion is 2014-07.
What conditions does trial NCT00949949 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Unresectable Gallbladder Cancer, Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer.
What interventions are being tested in trial NCT00949949?
The interventions under investigation include: cisplatin (DRUG), everolimus (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00949949?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00949949 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00949949's enrollment target sits among peer trials
38 48th of 83 higher than 35 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia